In this RCT, patients with an UGI bleed and high risk of recurrent bleeding (active bleeding, visible vessel, or adherent clot) recieved either high dose PPI (80mg bolus, then 8mg/hr for 3 days) or standard dose PPI (40mg bolus qday for 3 days). There was no difference between the groups in re-bleeding or units of transfused blood, but the standard dose group was much more likely to have a LOS <5 days. This indicates that standard dose PPI is not only clinically equivalent to high dose PPI therapy in reducing re-bleeding in high risk patients, but that it is also logistically preferable (abstract), as an accompanying editorialist agrees (editorial)
|
December 2, 2008 |
1 
Share This Post
One Comment
Leave A Comment
About the Author: Danielle Scheurer
Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.
Categories
Related Posts
November 8, 2019 |
0Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
June 29, 2013 |
0This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
June 22, 2013 |
0This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
I only read the abstract. I didn’t have time for the fulltext. I like the spirit of the article. But I am apprehensive about putting it into practice without additional consensus from the practicing gastroenterology and hospitalist community as well as additional literature. I am curious as to how others feel. I am also curious as to how people will respond in the clinical setting where a patient is continuing to bleed in spite of the 40-mg daily bolus.